RESUMEN
OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A). METHODS: For each disease a battery of at least four informative markers surrounding the tested gene were identified and for each family a protocol of multiplex fluorescent markers was developed and performed on single cells. RESULTS: PGD for PHHI was performed in three families. In family 1 two healthy children were born from different cycles, in family 2 three healthy children were born from two cycles, and in family 3 a healthy boy was born. For CAH in one family a healthy girl was born. One PGD cycle for Sanjat-Sakati resulted in a clinical pregnancy that was terminated due to high nuccal translucency (46X0). For one family with MEN 2A disease, the eighth PGD cycle resulted in birth of healthy twins. In all children genetic confirmation of the healthy status was performed. CONCLUSIONS: PGD is an effective method for preventing birth of affected children with endocrine disorders. Increasing the awareness of clinicians to the availability of these methods is most important.
Asunto(s)
Enfermedades del Desarrollo Óseo/genética , Enfermedades del Desarrollo Óseo/prevención & control , Enfermedades del Sistema Endocrino/genética , Enfermedades del Sistema Endocrino/prevención & control , Enfermedades Pancreáticas/genética , Enfermedades Pancreáticas/prevención & control , Diagnóstico Preimplantación/métodos , Anomalías Múltiples/genética , Anomalías Múltiples/prevención & control , Hiperplasia Suprarrenal Congénita/genética , Hiperplasia Suprarrenal Congénita/prevención & control , Adulto , Enfermedades del Desarrollo Óseo/congénito , Hiperinsulinismo Congénito , Transferencia de Embrión , Enfermedades del Sistema Endocrino/congénito , Salud de la Familia , Femenino , Marcadores Genéticos , Trastornos del Crecimiento/congénito , Trastornos del Crecimiento/genética , Trastornos del Crecimiento/prevención & control , Humanos , Hipoparatiroidismo/congénito , Hipoparatiroidismo/genética , Hipoparatiroidismo/prevención & control , Discapacidad Intelectual/genética , Discapacidad Intelectual/prevención & control , Israel , Masculino , Neoplasia Endocrina Múltiple Tipo 2a/congénito , Neoplasia Endocrina Múltiple Tipo 2a/genética , Neoplasia Endocrina Múltiple Tipo 2a/prevención & control , Nesidioblastosis/congénito , Nesidioblastosis/genética , Nesidioblastosis/prevención & control , Osteocondrodisplasias/congénito , Osteocondrodisplasias/genética , Osteocondrodisplasias/prevención & control , Enfermedades Pancreáticas/congénito , Embarazo , Resultado del Embarazo , Convulsiones/congénito , Convulsiones/genética , Convulsiones/prevención & controlRESUMEN
CONTEXT: Congenital hyperinsulinism (CH) may be treated conservatively in many children with octreotide given by multiple sc injections or via an insulin pump. OBJECTIVE: We describe two children treated with a once-monthly injection of a long-acting somatostatin analog. PATIENTS AND METHODS: Both patients presented with hypoglycemia 30 min after birth and were subsequently diagnosed with CH. Patients were initially treated with diazoxide, hydrochlorothiazide, frequent feedings, and octreotide via an insulin pump. With this therapy, they were normoglycemic with a good growth rate, normal weight gain, and excellent neurodevelopment. Treatment with the long-acting somatostatin analog lanreotide acetate (Somatuline Autogel), administered by deep sc injection of 30 mg once a month, was started at the ages of 4½ and 4 yr, respectively. Octreotide infusion was gradually weaned over 1 month. Continuous glucose monitoring after discontinuation of pump therapy showed normoglycemia. The first patient has now been treated with the lanreotide acetate for over 5 yr, and the second for 3 yr. Treatment is well-tolerated, and both the patients and their parents are satisfied with the transition from pump therapy to once-a-month injection and prefer it to pump therapy. CONCLUSION: Lanreotide acetate may be a safe and effective alternative to octreotide pump therapy in patients with CH, offering an improved quality of life. Longer follow-up of a larger patient group is needed.
Asunto(s)
Nesidioblastosis/tratamiento farmacológico , Péptidos Cíclicos/uso terapéutico , Somatostatina/análogos & derivados , Antineoplásicos/uso terapéutico , Antineoplásicos Hormonales/uso terapéutico , Hiperinsulinismo Congénito , Femenino , Humanos , Lactante , Recién Nacido , Inyecciones Subcutáneas , Masculino , Nesidioblastosis/congénito , Octreótido/uso terapéutico , Somatostatina/uso terapéutico , Resultado del TratamientoRESUMEN
Congenital hyperinsulinism is the most common cause of persistent hypoglycaemia in infancy. Early surgical intervention is usually required to prevent brain damage. The prevention of the transmission to the offspring is important in families carrying the mutated gene. Preimplantation genetic diagnosis (PGD) is an early genetic testing procedure for couples at risk of transmitting inherited diseases. A 36-year-old Saudi woman married to her first cousin with four affected children was referred for PGD. The hyperinsulinism disease was caused by a novel homozygous mutation in the KCNJ11 gene, an arginine 301 to proline (R301P) substitution.PGD was achieved by whole genome amplification followed by mutation detection combined with short tandem repeat identifier analysis in the first cycle and with haplotyping in the second cycle. The first and second cycles resulted in the births of healthy twin girls and a boy, respectively. As far as is known, this is the first application of PGD to hyperinsulinism. A feasible strategy including whole genome amplification followed by direct mutation detection combined with haplotyping is described.Utilizing haplotyping increases the efficiency of PGD diagnosis as well as confirming the genetic diagnosis. It reveals the parental origin of each inherited chromosome.